Objective: This phase Ⅲ study, which compared eribulin with capecitabine, showed a non-significant trend for superior overall survival ; however, no progression-free survival was noted.Pre-specified exploratory subgroup analyses that were previously presented showed that patients with triple-negative, ER-negative, or HER2-negative disease may have a greater benefit in OS with eribulin compared with capecitabine.In the present study, we present further pre-specified exploratory analyses of OS and PFS.